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Aim: 3D printing can be applied for point-of-care personalized treatment. This study 
aimed to determine the manufacturability and characteristics of 3D printed, drug-
loaded implants for alcohol misuse. Materials & methods: Disulfiram was the drug 
substance used and polylactic acid (PLA) the base material. Implantable devices were 
designed in silico. Drug and PLA were placed into the extruder to produce a 5% 
blend at 1.75-mm diameter. Material characterization included differential scanning 
calorimetry, thermogravimetric analysis plus inverse GC-surface energy analyzer. 
Results: Implantable constructs from the PLA feedstock were acquired. The extrusion 
processes had a detrimental effect on the active pharmaceutical ingredient-base 
blend. differential scanning calorimetry and thermogravimetric analysis analysis 
indicated drug–base interactions. Thermal history was found to influence inverse GC 
probe interaction. Conclusion: Drug-base incompatibilities must be considered during 
3D printing.
First draft submitted: 9 September 2016; Accepted for publication: 17 October 2016; 
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The ability to design and manufacture 
pharmaceutical dosage forms that are tai-
lored specifically for the patient is becoming 
increasingly important within the field of 
healthcare [1]. Personalized medicine offers 
the service provider with scope to custom-
ize treatment regimens based upon unique 
underlying genetic profiles. That is to say, 
variations in patient physiology, disease 
severity, drug responsiveness and side effect 
presentation may all be accounted for to 
permit optimal dosing schedules and attain 
effective disease management [2]. Clearly, 
this approach represents a paradigm shift 
from the ‘one size fits all’ strategy currently 
employed within modern day healthcare.
Recent developments within the field of 
pharmaceutical technology have provided 
innovative and evermore tangible methods 
to deliver personalized medicine to mem-
bers of the community; prime examples 
include ink-jet arrays [3] and 3D printing 
platforms [4]. As a result of the constantly 
decreasing size and cost of the units, poten-
tial now exists to offer individualized ser-
vices at the point-of-care. Appropriate sites 
for such service provision would include 
outpatient clinics within the secondary care 
setting or community pharmacy premises. 
Within such locations, the fabrication of 
a personalized dosage form could feasibly 
arise in response to a legally valid prescrip-
tion containing predefined patient details. 
Here, the healthcare provider (e.g., a phar-
macist) could manufacture a variety of dos-
age forms including tablets [5], oro-dispers-
ible wafers [3], suppositories and importantly 
for the work presented herein implant-
able devices for subsequent p rofessional 
a dministration [2].
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Implantable dosage forms allow for the delivery of 
active pharmaceutical ingredients (APIs) to the body 
over an extended period of time [6]; typical agents for 
delivery include contraceptives and hormone replace-
ment therapies. Such formulations confer a number of 
advantages to the user including the precise and steady 
release of API to achieve consistent plasma levels plus 
improved compliance with prescribed regimens and 
the ability to continue with life as normal. To date, 
limited consideration has been given to the formula-
tion of implantable devices for personalized medicine 
regimens and in this regard we believe that 3D print-
ing technology would lend itself well.
The process of 3D printing involves the accurate, 
layered deposition of a material to form a predeter-
mined solid object [7]. Traditionally, the approach has 
been employed to produce a range of nonmedical plas-
tic, metallic and ceramic architectures. However, more 
recently interest has been stimulated in this approach 
to support the field of healthcare [8].
This trend may be ascribed to several factors includ-
ing the exact control over construct arrangement, the 
capacity to control drug release profiles and the capa-
bility to personalize the dosage form to support patient 
needs [9]. A number of 3D printer subgroups are avail-
able to manufacture formulator-defined solid con-
structs; for instance, selective laser sintering [10], ther-
mal inkjet [3] and of interest herein fused deposition 
modeling (FDM) [4]. The latter strategy relies upon the 
synthesis of an in silico file that guides the trajectory 
of a heated, thermoplastic extrusion head in the x-y 
plane. The melted extrudate is deposited in a layer-like 
fashion with depth in the construct being achieved via 
movement of the baseplate in the z-plane [5]. As the 
material cools it hardens to the solid state, which may 
then be suitable for direct patient end use to support 
individualized disease management.
A number of polymers are currently available for 
use as base materials to support FDM. For example, 
polycaprolactone (PCL) and polyvinyl alcohol (PVA) 
may be applied to provide drug release over a period 
of hours [11], while polylactic acid (PLA) can offer the 
formulator release characteristics spanning days [2]. 
For illustration, in 2015 Goyanes and coworkers 
considered the suitability of PVA in controlling the 
release rate of aminosalicylate from tablets produced 
by FDM [11]. Here, an API saturated ethanol solution 
was prepared in which a PVA filament was immersed 
for 24 h. On drying, the group successfully produced 
tablets with predetermined dimensions and character-
ized the drug release profiles. This work underscored 
the fact that FDM offers healthcare providers a cheap 
and flexible way in which to produce dosage forms 
with variable infill percentages. Furthermore, in 2015 
Water and colleagues considered the application of 
PLA as the base filament for nitrofurantoin-loaded 
dosage forms [2]. Here, a microcompounder was used 
to incorporate PLA and nitrofurantoin. The blend was 
subsequently recirculated and extruded to support dos-
age form production. In a similar fashion to Goyanes 
and coworkers, this work highlighted the clear poten-
tial for 3D printing in the field of healthcare.
Sorption methods can be utilized to probe mate-
rial characteristics in order to predict behavior during 
manufacture and patient end use; such approaches 
may either be dynamic or static. Standard procedures 
such as the determination of the surface area by nitro-
gen adsorption at 77 K are based on the latter. In 
recent years, sorption methods have become increas-
ingly important since they provide several advantages 
over standard static techniques; including for example 
probe molecules can be chosen with chemical proper-
ties that are appropriate or relevant to the information 
required or problem to be addressed and may be site 
specific; vapor phase molecular probes are extremely 
sensitive probes for determining the surface chemistry 
at submonolayer coverages for particulate materials 
and typically, both kinetic and equilibrium thermo-
dynamic data can be obtained using molecular probe 
techniques [12].
For a sorption measurement, a carrier gas is used 
(instead of performed under vacuum) to transport 
the probe molecule (adsorptive) to the material under 
investigation (adsorbent). This allows faster equilibra-
tion under these experimental conditions. The most 
common sorption techniques are gravimetric methods 
and inverse GC (iGC). The iGC platform exchanges 
the roles of the phases in classical GC whereby the 
adsorbent under investigation is placed into a column 
while a known adsorptive is used in the gas phase. As 
in analytical GC, the retention time is obtained as the 
fundamental parameter measured. The retention time 
can be converted into a retention volume, which is 
directly related to several physicochemical properties 
of the solid (i.e., absorbent). These properties can be 
thermodynamic parameters, such as surface energy or 
heat of sorption and kinetic parameters, such as the 
diffusion constant and the activation energy of diffu-
sion. It is also possible to determine the uptake for both 
physisorption and chemisorption processes. In the first 
case, a sorption isotherm is obtained, which allows 
the computation of the surface area and heterogene-
ity profiles. In the latter case the amount adsorbed is 
much higher than the amount desorbed and a titration 
method is designed to calculate the amount irreversibly 
chemisorbed onto a surface. Apart from its high versa-
tility and speed, the main benefit of iGC is its sensitiv-
ity at the surface of the sample. Unlike most other sorp-
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tion techniques, iGC allows an accurate measurement 
at extremely low partial pressures. This makes iGC 
a valid tool in the determination of thermodynamic 
properties. It can operate in the Henry range (linear 
portion of the isotherm) where only high-energy sites 
are accessed by the probe molecule and there is no 
probe molecule-probe molecule interaction. The inter-
action with the high-energy sites allows the detection 
of very small differences between materials. For this 
reason, iGC has been used successfully in various cases 
for the investigation of batch-to-batch problems.
Based on a unique injection mechanism, the iGC 
surface energy analyzer (SEA) provides major improve-
ment in the injection pulse sizes allowing the BET 
region of the isotherm to be obtained; the approach has 
been applied to the work presented herein. The iGC 
SEA provides an unrivalled injection ratio of 1–4000, 
as compared with 1–60 of the iGC. If the surface area 
of the sample is provided, the iGC SEA can be auto-
matically programed to inject the precise amount of 
probe vapor in order to achieve different user defined 
surface coverages. The measurement of surface proper-
ties at different surface coverages will result in a surface 
heterogeneity profile of the sample. The understanding 
of energy distributions is particularly useful at interface 
boundaries of formulations, as well as to distinguish 
subtle differences in the surface chemistry of samples 
that may be used as either actives or base materials in 
disease management.
Alcohol dependence may be described as the physi-
cal or psychological obligation for an individual to 
consume alcohol-containing beverages [13]. The issue 
is of growing concern in the developed world. For 
example, alcohol misuse was recorded as the second 
highest cause for hospital admissions within the UK in 
2013–2014 [14]. Alcohol dependence may lead to acute 
and chronic health complications plus place significant 
strain upon healthcare systems. In the case of the for-
mer, individuals may regularly experience depression, 
anxiety and suffer mild-to-severe trauma [15]. Over 
the longer term there is an increased likelihood for the 
development of cancer, liver disease and the potential 
for psychological issues to present [16].
Current UK guidelines state that the pattern and 
severity of alcohol misuse should be initially investi-
gated on an individual patient basis [17]. Here, the aim 
should be for complete abstinence with the support of 
an assisted withdrawal program. Detail of the approach 
is beyond the remit of this study, however a number of 
therapeutic interventions can be made to help sustain 
total abstinence. Within the UK, disulfiram is pre-
scribed to manage alcohol dependence [18]. This agent 
inhibits the action of acetaldehyde dehydrogenase that 
is responsible for metabolizing alcohol on delivery to 
the body. The resulting effect leads to an increased 
concentration of acetaldehyde that causes flushing, 
increased body temperature and vomiting [19]. Such 
responses intend to deter the patient from consuming 
alcohol. Here, the patient must be fully compliant with 
medical guidance in order to attain the desired treat-
ment outcome (i.e., alcohol abstinence). Thus, a key 
drawback with the approach is that the patient may 
consciously decide not to administer the API on a daily 
basis. One possible route to circumvent this treatment-
limiting drawback would be to deliver the API as an 
implantable device.
This study aims to fabricate disulfiram-containing 
implants via FDM 3D printing and evaluate result-
ing material properties. Here, we have chosen PLA as 
the model base material for study as it is biodegrad-
able and biocompatible plus it may facilitate controlled 
drug release over hours when delivered to the body [2]. 
Within this work we shall offer comment upon the 
feasibility of the approach/use of materials, or not, for 
chronic disease management at the point-of-care.
Materials & methods
Materials
A PLA filament spool, of 1.75 ± 0.05 mm diam-
eter, was purchased from Wanhao Inc. (FL, USA; 
BN: 201505051508003). Disulfiram of 97% purity 
was acquired from Acros Organics (NJ, USA; BN: 
A0146315); the chemical structure of the compound 
is presented in Figure 1. During this work, ScotchBlue 
professional tape was used as the surface on which to 
print.
Methods
Preparation of the disulfiram-PLA filament
Initially, 280 g of PLA feedstock was cut into small 
fragments of approximately 1–2 cm in length. The 
material was subsequently placed into an oven set at 
60°C for 2 h to remove adsorbed moisture. Appropri-
ate amounts of API and base were taken and weighed 
using a five-place analytical balance (A&D, BM-252; 
CA, USA) so as to satisfy a 5% PLA-disulfiram blend. 
In addition, a sample of the preconditioned PLA was 
taken for use as the placebo. The API and base mate-
rials were gradually fed into a Noztek Pro filament 
extruder (West Sussex, UK) to allow for mixing and 
drug-loaded filament production. With respect to the 
5% PLA-disulfiram blend, one batch was extruded at 
140°C and the other at 170°C. The control sample 
was extruded at 170°C, with one recirculation phase 
through the extruder unit. In order to ensure uniform 
mixing the API-containing extrudate was recycled 
through the extruder a further time. Upon comple-
tion, the filaments were stored in a vacuum desiccator 
4 J. 3D Print. Med. (2016) 1(1)
Figure 1. Disulfiram.
Figure 2. A rendered image of the implant of fixed dimensions 40 mm 
length and 3 mm diameter.
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until required for printing in order to guard against 
moisture adsorption.
Implant printing
The constructs were generated using the Wanhao 
Duplicator 4 Desktop 3D printer (Wanhao Inc., 
FL, USA). The architecture of each dosage form was 
defined using the SolidWorks® Education Edition 
2015–2016 SP3.0 software platform (Dassault Sys-
temes, France). In order to prepare the design files for 
3D printing MakerWare 2.2 software was employed 
(NY, USA). The implant dimensions were fixed at 40 
mm in length and 3 mm in diameter so as to reflect 
the dimensions of commercially available implantable 
products [20]. A rendered image of the implant device 
devised for this work is shown in Figure 2.
Throughout the design and manufacturing process 
various parameters were selected for product optimiza-
tion. For example, prior to fabrication, features such 
as standard PLA resolution, building plate temperature 
of 20°C, layer height of 200 μm, extrusion tempera-
ture of 210°C, extrusion speed of 90 mm/s and travel 
speed of 150 mm/s and infill percentage of 100% were 
confirmed within the software packages. In total, ten 
implants were printed using the native PLA feedstock 
and a further ten were printed using extruded PLA.
Material characterization
Determination of filament morphology
Samples of the PLA feedstock, extruded PLA, 5% 
PLA-disulfiram blend extruded at 140°C and 5% 
PLA-disulfiram blend extruded at 170°C were mea-
sured using a digital calliper. In order to quantitatively 
assess variability along a fixed length of the filaments, a 
5 cm sample was taken and the width was recorded at 1 
cm intervals. In addition, photographs of the filaments 
were taken using a Nikon D60 digital single lens reflex 
camera (Nikon, Japan) with the macro mode selected.
Determination of implant morphology & mass
Dimensions of the implants were measured using a 
digital calliper. The mass of each implant produced 
was determined by a 5-place analytical balance (AND, 
BM-252; CA, USA). Once again, images of the gross 
structures were collected using a Nikon D60 digi-
tal single lens reflex camera (Nikon, Japan) with the 
macro mode selected.
Scanning electron microscopy
Scanning electron microscopy (SEM) (Quanta 200 
SEM, FEI, Holland) was utilized to visualize the gross 
morphology of the filaments and the implants. Here, 
the samples were dried and placed on double sided 
carbon tape ready for coating. Thereafter the samples 
were coated at 25 milliamps, approximately 15 nm 
coat, in a K550X sputter coater (Emitech, UK) with 
palladium in an argon atmosphere. Subsequently, the 
material was scanned using an acceleration voltage of 
10 kV at a working distance of approximately 10 mm.
Thermal analysis of filaments & implants
Differential scanning calorimetry
A Perkin Elmer DSC7 (WA, USA) was employed to 
perform the thermal analysis. An average sample mass 
of 5.85 mg was taken for the native disulfiram, PLA 
feedstock, extruded PLA, 5% PLA-disulfiram blend 
extruded at 140°C, 5% PLA-disulfiram blend extruded 
at 170°C, implant printed from the PLA feedstock and 
the implant printed from the extruded PLA. In each 
case, the samples were placed directly into a Perkin 
Elmer aluminium pan (Shelton, USA; BN: 02190041) 
prior to analysis. Nitrogen was used as the purge gas (20 
ml/min) and the heating rate was 10°C/min starting at 
room temperature (e.g., 25°C). The data were collected 
and analyzed using Pyris Series software (v 3.80).
Thermogravimetric analysis
A TGA Q50 (TA instruments) was employed to con-
duct further thermal analysis. An average mass of 14 
mg of disulfiram, PLA feedstock, extruded PLA, 5% 
PLA-disulfiram blend extruded at 140°C, 5% PLA-
disulfiram blend extruded at 170°C, implant printed 
from the PLA feedstock and the implant printed from 
the extruded PLA were placed into a platinum pan. 
Nitrogen was used as a purge gas with a balance flow 
rate of 40 ml/min and sample flow rate of 60 ml/min, 
the heating rate was 10°C/min starting at room tem-
perature (e.g., 25°C) and the mode was TGA 1000 
in a ramp format. Data were collected using QSeries 
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(Q50–1145 = TGA Q50) and analyzed using Univer-
sal Analysis 2000 software (v 4.5A). The settings were 
modified slightly to conduct the thermal analysis of 
disulfiram to investigate the effect of exposure to tem-
peratures of 170°C for 30 min. Here, all parameters 
remained constant, however the mode was TGA 1000 
in a heat and hold format.
iGC analysis
All analyses were carried out using iGC-SSEA [21]. The 
data were analyzed using both standard and advanced 
SEA Analysis Software (Cirrus Plus Analysis Software, 
v.1.2.1). Approximately 100–170 mg of the samples 
were packed into individual iGC silanized glass col-
umn, and was run at a series of surface coverage with 
alkanes and polar probe molecules to determine the 
dispersive surface energy (γ
S
D) as well as the acid-base 
free energy of adsorption (ΔG
SP
). In this study, the 
sample column was preconditioned for 2 h at 30°C 
and 0% RH with 10 ml/min helium carrier gas. The 
experiment was conducted at 30°C with 10 ml/min 
total flow rate of helium, and using methane for dead 
volume corrections.
Results
Material visualization
At the outset, variable blends of the base material/
API were obtained or extruded to form single filament 
strands (Figures 3A–D). Subsequently, the PLA feed-
stock strand (Figure 3A) and the extruded PLA strand 
(Figure 3B) were loaded into the FDM 3D printer to 
produce implantable devices (Figure 3E & F).
The native PLA feedstock (Figure 3A) and extruded 
PLA (Figure 3B) presented as white, single filament 
strands that were able to pass through the head of the 
FDM 3D printer. On inspection, the extruded PLA 
was thinner and appeared to demonstrate numerous 
undulations across the entire length. On the introduc-
tion and subsequent blending of disulfiram at 140°C, 
the filament became discolored and nonuniform 
(Figure 3C). This observation was more apparent when 
the material was extruded at the higher operating tem-
perature of 170°C (Figure 3D). Here, the outer surface 
was darker and more irregular in shape. With regard to 
the implant devices, the dosage form produced using 
the PLA feedstock presented as a smooth construct 
(Figure 3E), while the implant produced from the 
extruded PLA exhibited distinct layers plus a number 
of structural defects (Figure 3F).
Filament & implant analysis
In order to investigate the cross-sectional uniformity 
of the PLA feedstock/extruded filaments digital calli-
per measurements were taken. Here, a representative 
sample of 5 cm length of each material was examined 
and measurements were recorded at 1 cm intervals. 
The data were averaged and recorded in Table 1.
The data presented in Table 1 are supportive of the 
visual inspections presented above. That is to say, 
the cross-sectional uniformity of the filaments varied 
according to the conditions the material was exposed 
to. As anticipated, the native PLA feedstock demon-
strated minimal variation over the 5 cm sample length. 
However, on extrusion the variation increased as dem-
onstrated by the larger SD presented in Table 1. Once 
the drug was incorporated into the blend, the variation 
increased further and the 5% PLA-disulfiram blend 
extruded at 140°C resulted in an increased diameter by 
0.72 mm than that of the extruded PLA with a three-
times greater variation along the sample length. The 
5% PLA-disulfiram blend extruded at 170°C resulted 
in even greater variation.
On extrusion, this blend was very inconsistent with 
parts in liquid form and others congregating at the 
extruder exit in thick bulbous structures. Further to 
this, when the 5% PLA-disulfiram filament was being 
extruded at 170°C a noticeable, unpleasant odor was 
produced suggesting the release of sulfur from degra-
dation of the API (Figure 1). Subsequently, the mass 
and measurements of the 3D printed implants were 
investigated; the data are presented in Table 2.
The implants produced using extruded PLA were of 
lower mass, width, length and volume and generally 
demonstrated greater variation in these terms when 
compared to those generated from the native PLA 
feedstock. As a result of the thinner extrudate diam-
eter (e.g., 1.70 mm ave, as per Table 1) gentle force 
was required to encourage feed through the FDM 3D 
printer head. This was so because the rotating feeder 
heads could not fully grip the extrudate to move it 
toward the heated printer nozzle. Naturally, such 
undesirable intervention would have contributed to the 
varied deposition of layers thus leading to greater vari-
ety in mass, width, length and volume measurements. 
In terms of width and length, the variation within 
the batches was similar for both PLA feedstock and 
extruded PLA. Implants printed using the extruded 
PLA were consistently lighter and smaller than those 
produced from the PLA feedstock.
SEM analysis of filament & implant morphology
A selection of SEM images demonstrating the gross 
morphology of the disulfiram starting material plus 
the 3D PLA/extruded filaments and implants are pre-
sented in Figures 4 & 5, respectively.
The disulfiram starting material was pellet based, 
formed from the cohesion of numerous drug-contain-
ing microgranules. On observation, a number of gran-
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Figure 3. Images of the filaments and implant devices.(A) Polylactic acid 
(PLA) feedstock, (B) extruded PLA, (C) 5% PLA–disulfiram blend extruded 
at 140°C (D) 5% PLA–disulfiram blend extruded at 170°C, (E) implant 3D 
printed using the PLA feedstock and (F) implant 3D printed using the 
extruded PLA.
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ules are distributed over the supporting base which will 
have sloughed from the main pellet as a result of weak, 
nonspecific interparticulate forces.
SEM images of the PLA feedstock illustrate a 
smooth surface of the filament (Figure 5A). How-
ever, upon extrusion the surface appeared to become 
more irregular with a rougher surface (Figure 5B). As 
the drug was incorporated into the blend at the lower 
operating temperature of 140°C, there was an increase 
in surface roughness (Figure 5C). Furthermore, the 
irregularity in the filament also became more obvious. 
Once the temperature was increased to 170°C, the fila-
ment surface became considerably smoother however 
the asymmetrical nature of the strand was more promi-
nent (Figure 5D). The images of the implants clearly 
show the layers that have deposited by the 3D printer 
in order to produce the construct. The layers forming 
the implant from the PLA feedstock (Figure 5E) appear 
much sharper and more consistent than those from the 
extruded strand of PLA (Figure 5F).
Thermal analysis
The API along with all of the prepared samples were 
characterized by thermal analysis. Differential scan-
ning calorimetry (DSC) data indicate that disulfiram 
melts at 72.2°C, with no observable exo- or endother-
mic events prior to this temperature. The thermogravi-
metric analysis (TGA) suggested a 17% weight loss 
following a 30 min isothermal run at the extrusion 
temperature of 170°C, as detailed in Figure 6.
Furthermore, a noisy baseline in the DSC data fol-
lowing the PLA melt in the 5% PLA-disulfiram blend 
extruded at 170°C was noted, as detailed in Figure 8. 
This point was not observed with other samples. Thus, 
the data are indicative of the fact that disulfiram 
degrades upon exposure to high temperatures over an 
extended period of time.
The filaments and implants, with or without disul-
firam, all displayed similar cycles. A single glass transi-
tion event occurred at 57.8°C (±4.0°C) and a single 
melting point displayed at 166.4°C (±2.7°C), which 
corresponds to previously reported figures [22]. The 
glass transition point of the PLA feedstock in compari-
son to the other samples, which had undergone oven 
drying followed by extrusion, was much more defined. 
This suggesting that PLA becomes more amorphous 
once it has been exposed to heat. An exothermic event 
was displayed between the temperatures of 88.9°C and 
106.7°C on all cycles, which could potentially relate to 
the rearrangement of the polymer chains within PLA 
matrix. The 5% PLA-disulfiram blends extruded at 
140°C and 170°C showed no evidence of the drug melt 
at 72.2°C, but the PLA melt at 166°C was still present. 
TGA data showed no significant mass loss therefore it 
can be inferred that disulfiram is dispersed in PLA as 
a solid solution.
On DSC analysis, the native PLA feedstock dis-
played a number of exothermic and endothermic 
transitions, as detailed in Figure 7. However, once the 
material had been extruded only a small glass transi-
tion point, a single exothermic event and a melt were 
identified. In this case, the thermal transitions are less 
Table 1. Measured properties of the filaments (5 cm length).
Sample Average diameter ± SD (mm)
PLA feedstock 1.72 (±0.01)
Extruded PLA 1.70 (±0.07)
5% PLA–disulfiram 140°C 2.42 (±0.21)
5% PLA–disulfiram 170°C 1.95 (±0.37)
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Figure 4. Scanning electron microscopy image of a disulfiram aggregate.
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defined in their presentation. Further to this, DSC 
analysis was conducted on the extruded PLA plus the 
5% PLA-disulfiram blends extruded at 140 and 170°C, 
typical results are illustrated in Figure 8.
The incorporation of disulfiram within PLA further 
changes the transitional behavior of the polymer. As 
noted previously, a glass transition stage is visible along 
with the exothermic event and the melt. However, the 
trace is not as smooth as the plot detailing the absence 
of drug. The exothermic event noted in the case of 
the blend extruded at 170°C has a lower enthalpy 
of crystallisation (e.g., 1.632 J/g) when compared to 
the extruded filament without disulfiram and when 
extruded at 140°C, 6.439 and 7.586 J/g respectively. 
Furthermore, the enthalpy of the melt is much larger 
when extruded at 170°C with a value of 25.460 J/g in 
comparison to the extruded without drug, 5.597 J/g 
and when extruded at 140°C, 14.080 J/g. In addition 
to this, the 3D printing process also resulted in differ-
ences in the behavior of the polymer, as demonstrated 
in Figure 9.
Upon inspection of the data presented in Figure 9, 
it is evident that the glass transition peak occurs at a 
slightly lower temperature of 58°C once the material 
has been passed through the 3D printer. In addition, 
the exothermic event for the material occurs at the 
higher temperature of 106°C. This is the highest tem-
perature of which the exothermic event was observed 
for all six samples. Moreover, the trace is smoother 
with less transitions presenting when compared with 
the native material.
iGC: surface energy analysis
Surface energy is known to be associated with the 
chemical composition and the level of crystallization 
of a sample of interest [23]. This parameter may influ-
ence the reaction(s) of a material within different envi-
ronments, which is important for implantable devices. 
One relevant area of study is the surface energy profile 
of a material (i.e., drug-loaded feedstock) in different 
environments with different processing parameters, in 
particular the thermal history.
Here, we considered two samples acquired under 
different processing conditions. One specimen is an 
extruded 140°C PLA-drug blend with normal air 
cooling (i.e., designated as PLA + drug noncooled), 
the other is an extruded 140°C PLA-drug mix with 
faster cooling in ice water (designated as PLA + drug 
cooled). The data presented in Figure 10A outline the 
dispersive energy profile of the materials as function of 
surface coverage. Upon inspection, there is no major 
difference in the dispersive energy term between each 
sample. Based on the van Oss approach [24], the spe-
cific surface energies (γ
S
AB) of the samples were calcu-
lated using a pair of monofunctional acidic and basic 
probe molecules (i.e., chloroform – γ+: 1.27 mJ/m2 and 
ethyl acetate – γ−: 475.67 mJ/m2) and the Della Volpe 
scale was employed. The information presented in 
Figure 10B confirms that there are stronger variations 
between the two samples, but in general the difference 
between the two sets of data on specific energy is not 
significant.
The iGC-SEA data acquired with different solvents 
are significantly different as shown in Figure 11A & B. 
The specific (acid–base) Gibbs free energy of adsorp-
tion ΔG
SP
 changes with surface coverage, indicating 
the heterogeneous nature of the samples. The ΔG
SP
 
profiles reflect the interactions with all four polar 
probe molecules. Higher ΔG
SP
 values can be attributed 
to a higher concentration of polar surface groups or 
Table 2. Measured properties of the implants (n = 10).
Source Average mass ± SD 
(mg)
Average width ± SD 
(mm)
Average length ± 
SD (mm)
Average volume ± 
SD (mm3)
PLA feedstock 343.78 (±16.36) 3.34 (±0.11) 38.17 (±0.21) 334.12 (±22.01)
Extruded PLA 306.87 (±39.98) 3.15 (±0.15) 37.89 (±0.20) 296.47 (±29.03)
PLA: Polylactic acid.
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Figure 5. Scanning electron microscopy images of the filaments and 
implant devices.(A) Polylactic acid (PLA feedstock), (B) extruded PLA, (C) 
5% PLA-disulfiram blend extruded at 140°C, (D) 5% PLA–disulfiram blend 
extruded at 170°C, (E) implant 3D printed using the PLA feedstock and (F) 
implant 3D printed using the extruded PLA.
A B
C D
E F
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different surface groups with higher specific surface 
energy. As shown in Figure 11A & B, all samples show 
strong degree of interactions with all polar probes. The 
surface chemistry of the samples was assessed using 
the Gutmann acid (K
a
) and base (K
b
) numbers, deter-
mined based on the Gutmann approach [25] using the 
following polar probes: dichloromethane, ethyl acetate 
and chloroform. The K
a
 and K
b
 values of the samples 
were calculated using the ΔG
SP
 values of polar probes 
at 0.01 surface coverage and the results are presented 
in Figure 12. The Ka/Kb ratio provides an empirical 
basis for classification of surface with respect to acid-
ity–basicity. It is so called surface specific character 
(Sc). If the ratio is Sc > 1 the surface is considered to be 
acidic (i.e., electron acceptor ability prevails over elec-
tron donor capacity). A Sc < 1 shows basic c haracter 
whereas Sc ≈ 1 is the characteristic of amphoteric sur-
faces.
The surface of the samples show different acid–base 
character. The noncooled sample is less basic in nature 
than the cooled sample, having lower basic constant. 
The clear differences observed between the two sam-
ples suggest that the thermal history of the drug-loaded 
feed is an important variable to be controlled for this 
particular application (i.e., implant production).
Discussion
Overview
Significant interest now lies in the field of 3D printing 
to support the personalized medicine paradigm. The 
ability to manufacture tailored pharmaceutical formu-
lations at the point-of-care is an exciting and imminent 
prospect. Such development may be ascribed to recent 
advances in both engineering technology (i.e., FDM) 
and a more detailed understanding of patient phar-
macogenomics. Clearly, in order for the strategy to 
be effective it is imperative to fully understand the 
interactions between the API(s) of interest and base 
material(s) and their related manufacturability. To this 
end, the present study has considered the feasibility of 
producing API-loaded PLA implants via FDM with 
related materials characterization. Key recommenda-
tions are provided here in order to support future pro-
gression within this discipline of pharmaceutics.
Exemplar study
Our current study is based upon that conducted by 
Water and colleagues in 2015, who effectively loaded 
a PLA filament with nitrofurantoin to produce a cus-
tom feedstock suitable for 3D printing [2]. During the 
work, the group successfully prepared matrix concen-
trations of 10, 20 and 30% nitrofurantoin. Subse-
quently, the appropriately weighed PLA and API were 
fed into the extruder screw channel and underwent 2 
min of recirculation before being ejected as a single 
strand with an average diameter 1.6 ± 0.1 mm. The 
constructs were designed as disks with predetermined 
dimensions of 10 mm diameter × 2 mm depth and 
were successfully produced via MakerBot Replicator 
2 3D printer utilising the custom filament created. 
Analysis of the construct mass (n = 3) indicated that 
the lower the nitrofurantoin percentage the greater 
the variation in weight. Furthermore, SEM images of 
both the extruded filaments and disk constructs con-
firmed an apparent rougher surface with increased 
drug loading, which was ascribed to the presence 
of solid nitrofurantoin within the PLA matrix. 
This point was further confirmed by x-ray diffrac-
tion (XRD) analysis that highlighted nitrofurantoin 
anhydrate crystals within the disks.
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Figure 6. Thermogravimetric analysis data for disulfiram with an isothermal hold at 170°C for 30 min.
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Thermal analysis demonstrated a single glass transi-
tion event at 56.6 ± 0.7°C, a melting point at 149.6 
± 0.5°C with no evidence of recrystallization. Due to 
the absence of a melting point for nitrofurantoin below 
235°C, it was inferred that the PLA-nitrofurantoin 
blend consisted of two immiscible phases. Drug release 
profiling was conducted over a period of 45 days. Ini-
tially, burst release was observed, within the first 3 
h, with the highest rate of release for the subsequent 
2 days before steadily decreasing over the remaining 
period. The degree of drug release correlated to the 
drug loading (i.e., the greater the drug loading, the 
greater the rate of drug release). Overall, the approach 
was deemed as a successful way by which to manufac-
ture drug-eluting constructs demonstrating antimicro-
bial activity.
Material characteristics
Despite applying the approach taken by Water and 
coworkers, we were unsuccessful in our attempt to 
manufacture disulfiram-loaded PLA implants to sat-
isfy the personalized medicine paradigm. We attribute 
the outcome to a number of factors but primarily to 
API-base incompatibilities at elevated manufacturing 
temperatures. In order to further the knowledge-base 
in this sphere of pharmaceutics, we believe that it is 
important to evaluate the processes undertaken, char-
acterize resultant material properties and provide rec-
ommendations going forward.
The inherent material incompatibilities led to 
incongruity in the drug-base filament. This fact 
in turn resulted in an inability to effectively print 
because the filament diameter no longer matched the 
inlet configuration of the 3D printer head. We believe 
that the diameter of the extruded material is depen-
dent upon a number of factors; primarily the nozzle 
size dictates the thickness of the produced material, 
however, base viscoelastic properties also have an 
influence. The viscoelastic profile of a material is an 
essential consideration. The resultant swelling of the 
PLA on release from the extruder nozzle may be influ-
enced by parameters such as screw speed and extru-
sion temperature. Although the extruded PLA with-
out API was able to be fed through the printer head, 
the need for application of pressure to encourage the 
feed led to inconsistencies in the resulting printed 
implants.
Thermal analysis
Thermal analysis highlighted further issues with the 
FDM approach. On consideration of the DSC data 
presented herein, it is clear that an elevation in operat-
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Figure 7. Differential scanning calorimetry plots for polylactic acid feedstock and extruded polylactic acid. 
PLA: Polylactic acid. 
Figure 8. Differential scanning calorimetry plots for extruded polylactic acid and 5% polylactic acid–disulfiram 
blends extruded at 140 and 170°C. 
PLA: Polylactic acid.
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ing temperature led to the modification of viscoelastic 
behavior of PLA. Furthermore, processing at a tem-
perature of 170°C caused the API to degrade, a point 
corroborated by the TGA cycle in Figure 6 and the 
noisy baseline in Figure 8. However, the TGA cycle of 
the API in ramp format did not show as significant a 
weight loss when compared with the isothermal hold. 
Thus, we infer that API degrades upon exposure 
to high temperatures over an extended period. The 
latter point is central to the feasibility of the FDM 
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Figure 9. Differential scanning calorimetry plots for polylactic acid feedstock and 3D printed implant using 
polylactic acid feedstock. 
PLA: Polylactic acid.
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approach when operating at elevated temperatures 
at the point-of-care. This is so because the extrusion 
process typically involves the drug–base blend being 
exposed to high temperatures for approximately 30 
min during translocation along the screw thread.
We believe that the manufacturing conditions 
would have led to the degradation of the API within 
this study resulting in the disagreeable drug-contain-
ing filament produced and the unpleasant sulfuric 
odor. Interestingly, not only does the API appears to 
be affected by the required conditions, the PLA itself 
has shown a transition from the feedstock material 
to the extruded material. An alteration in the poly-
mer composition/arrangement could have contrib-
uted to this change in behavior and consequently 
the properties of the PLA. Furthermore, the printing 
process highlighted modifications to the PLA transi-
tion characteristics. The high temperature exposure 
is consistent between both the extrusion and print-
ing processes therefore it is likely to be the leading 
factor for these variations. Alongside the manufactur-
ing processes themselves, the API appears to have an 
impact on the PLA. Here, the key transitions were 
evident (i.e., the glass transition) along with a possible 
recrystallization and a melt. However, the extruded 
PLA being much smoother in terms of its trace could 
be indicative of the PLA–disulfiram blend being a 
more crystalline structure.
We conclude, therefore, that there is indeed an 
interaction between disulfiram and PLA. Further to 
this, the enthalpy of crystallization was much lower, 
1.632 J/g, when disulfiram was incorporated at 170°C 
indicating that less energy was required to encourage 
this recrystallization process. Both the blends were 
notably more brittle upon handling in contrast to 
the flexible PLA feedstock. The exemplar study did 
not report any changes in DSC data upon addition 
of their API.
Surface energetics assessment
Within this study, the iGC-SEA was applied to deter-
mine the surface energetics and surface chemistry 
(i.e., relative basicity) of the extruded samples pro-
duced at 140°C. This study was able to differenti-
ate the differences in surface energetics and surface 
chemistry (e.g., relative basicity) of the samples. The 
surface energetics and surface chemistry of materials 
are known to have important implications in pro-
cesses involving interfacial interactions such as wet-
ting, coating along with cohesion and adhesion. The 
data demonstrate that the samples are energetically 
heterogeneous, meaning the surface energy changes 
as a function of surface coverage. In addition, it can 
be clearly observed that the dispersive component 
contributes a major part of the surface energy. The 
specific free energies and Gutmann acid/base values 
indicate that the surfaces of the samples are more 
basic in nature. This means that the samples possess 
higher concentrations of electron-donating surface 
functional groups.
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Figure 10.  Inverse gas chromatography analysis, as a function of surface coverage, of drug–base combination 
with thermal history considered. (A) Comparison of the dispersive surface energy profile, as a function of surface 
coverage. (B) Comparison of the specific surface energy profile, as a function of surface coverage. 
PLA: Polylactic acid.
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Figure 11.  Inverse gas chromatography analysis of drug–base combination with thermal history considered. 
(A) Specific (acid-base) free energy profiles of different solvents for the polylactic acid + drug cooled sample. (B) 
Specific (acid-base) free energy profiles of different solvents for the polylactic acid + drug noncooled sample. 
PLA: Polylactic acid.
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Figure 12. Gutmann acid and base constants of the samples at a certain surface coverage. 
PLA: Polylactic acid.
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Limitations & recommendations
Limitations
The equipment used during this study (e.g., Noztek 
Pro Extruder & Wanhao 3D Printer) also contrib-
uted to the lack of success. As such, when establishing 
a laboratory space we recommend that the user con-
siders operational tolerances for all pieces of equip-
ment. Ideally, tolerances should be flexible but within 
range to allow for slight variation in material proper-
ties (e.g., feedstock diameter) that will inevitably arise 
during the preparative stages. In addition, during the 
manufacture of blend-based pharmaceutical formu-
lations it would seem appropriate to have available a 
controlled feed to allow the ready addition of the API 
in a consistent manner plus a recirculation channel to 
allow effective mixing and minimize material losses. 
For example, Water and colleagues used a DSM Xplore 
micro compounder which accommodated 2 min of 
mixing prior to extrusion [2].
The diameter of the extruder nozzle is a crucial 
factor to consider for optimal filament generation. 
Here, the user should ensure that the nozzle is of the 
appropriate size (e.g., 1.75 mm) such that the resultant 
filament will match the inlet configuration of the 3D 
printer head. However, that being said, the viscoelas-
tic nature of the base polymer, and indeed the drug–
base blend, should be borne in mind. On release of the 
molten material from the nozzle there is potential for 
the material to swell and bulge [2]. Thus, the resulting 
variation in the diameter of the feed may be unsuit-
able for insertion into the 3D printer head. One way in 
which to circumvent this issue is to modify the operat-
ing temperature slightly and in such a way account for 
polymer swelling on release from the extruder nozzle. 
Additionally, gravitational forces also influenced the 
diameter of the extruded filament in this study. As 
the length of the filament increased the weight pulling 
on the swollen extrudate also increased and the thin-
ner the strand became. Thus, we advocate the use of 
a lubricated, plate-like structure in proximity to the 
nozzle to adequately support the extrudate on release 
from the nozzle to maintain a consistent diameter.
The 3D printer employed during this study cer-
tainly contributed to the difficulties experienced. The 
high-precision requirement for the filament diameter 
made the printing process very challenging. If the fila-
ment (drug loaded or not) deviated from the diameter 
of 1.75 mm then the feed system would either not 
detect its presence or clog. We suggest, therefore, that 
an adjustable clamp inside this mechanism would be 
beneficial to allow the feed of filaments that may be for 
instance of 1.75 ± 0.1 mm. Additionally, improved res-
olution would provide a smoother, more aesthetically 
pleasing finish to the dosage forms produced and as 
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such instills greater patient confidence. This is a prime 
consideration to take into account ahead of purchasing 
such a unit. Here, we believe that investment in the 
most precise 3D printer would certainly be beneficial 
for the formulator over time.
The greatest limitation to study success was the 
incompatibility between the base material and API. We 
believe that base material selection must be determined 
by considering four key elements; namely the safety 
profile of the material, manufacturability (including 
drug–base incompatibilities), drug release characteris-
tics and material degradation over time. As previously 
stated, PLA is biodegradable and demonstrates a drug 
release profile covering a number of days, thus making it 
an ideal material for implantable devices. However, the 
work presented herein clearly demonstrates that great 
care must be taken during the manufacturing process.
It is simply not the case to select the base material on 
one ‘topic,’ a delicate interplay exists between the base 
material and API of interest. In order to develop cur-
rent understanding of drug–base incompatibilities it is 
important to apply a range of advanced materials char-
acterization techniques, including for example DSC and 
x-ray diffraction. Our observations within the labora-
tory and data collected in respect of the resultant mate-
rials confirm that high operating temperatures have to 
be carefully considered before manufacture and ideally 
prescreening of all materials for inclusion in the final 
formulation must take place prior to manufacture.
Recommendations
We believe that there is a pressing need to investi-
gate alternative base materials, of lower melting 
temperature, such that the potential of 3D printing 
may be fully realized when considering personal-
ized medicine paradigms. A prime example is that 
of PEG, which has a melting range of between 50 
and 60°C [26]. However, care must be taken to ensure 
biocompatibility. This point is acutely illustrated by 
the warning issued by the US FDA in 2011 regard-
ing PEG 3350 (i.e., Miralax®) and the potential for 
 neuropsychiatric events on ingestion [27].
Similarly, PCL has a lower melting temperature of 
approximately 60°C with a high thermal stability [28]. 
This base material has application in the field of tis-
sue engineering via 3D printing as a result of its bio-
compatible, biodegradable, pore interconnectivity and 
porosity profile. Furthermore, PCL has reported use 
in pharmaceutical dosage forms. In 2015, Pathak and 
coworkers successfully manufactured PCL matrices 
loaded with doxycycline to be administered via the 
vaginal route for the treatment of sexually transmitted 
infections [29]. Thus, PCL could prove to be a suitable 
excipient for use in drug-eluting constructs in the field 
of FDM.
Naturally occurring products may also hold promise 
as base materials for FDM; examples include stearic 
acid and oleic acid. Both materials have been success-
fully applied as support species for hydroxypropyl-
methylcellulose-based constructs in 3D printing strat-
egies [30]. Once again, they are of low melting point, 
namely 70°C and 13–14°C, respectively [31], and there-
fore have the potential to create a more suitable pro-
duction environment during the printing process.
Clearly, if the API does degrade during the formu-
lation process then it will no longer hold therapeutic 
value. Accordingly, if we give consideration to the 
model API employed within this study, in order to 
ensure activity on delivery to the body we would require 
formulation with a biodegradable/biocompatible poly-
mer of significantly lower melting point (e.g., 60°C) 
as compared with the high operating temperatures 
noted with PLA. In the same manner, a large num-
ber of APIs will experience similar deleterious effects 
at elevated temperatures, which may be exemplified on 
consideration of the first-generation antihistamine pro-
methazine that is commonly used as an antiemetic [32]. 
Hence, we underscore the fact that great attention is 
needed to establish the suitability of the operating 
conditions during the 3D manufacturing process. All 
materials should be taken on their individual merits 
at the outset and carefully monitored on combination.
Application to healthcare
Despite our study having limited success with regard 
to producing personalized implantable formulations to 
manage alcohol misuse, potential undoubtedly exists 
for the application of 3D printing within the healthcare 
arena. Here, we have demonstrated that it is imperative 
to carefully consider the nature of each material in the 
manufacturing process plus related operating condi-
tions. The 3D printer employed herein was of compact 
size and therefore ideal for installation and use at the 
point-of-care. A prime example of this very approach is 
the personalization of medicine administration within 
the community pharmacy setting. Clearly, such a strat-
egy would allow for the patient to be considered on 
an individual basis in terms of their dose requirements 
and related side effect presentation. Once a patient 
is electronically logged within the pharmacy system 
(i.e., correct determination of their patient specific file) 
then their details can be utilized for efficient and accu-
rate 3D printer dispensing.
Conclusion
This study attempted to manufacture disulfiram-
loaded implants via FDM using PLA as the base mate-
rial. An assessment of the feasibility to utilize these 
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materials with this method was also carried out. Here, 
the considerable degradation of disulfiram during the 
extrusion process and change in PLA characteristics 
when extruded highlights the considerations that need 
to be taken for the process to be successful. The high 
extrusion and printing temperatures required created 
a number of problems therefore materials with a lower 
melting point need to be obtained and utilized to 
allow for printing at temperatures below decomposi-
tion values. Moreover, potential interactions between 
the base material and the API need to be thoroughly 
investigated prior to manufacturing to avoid any 
untoward changes in material composition. By utiliz-
ing 3D printing there is potential to produce person-
alized healthcare on a small scale to optimize dosing 
regimens for patients. Suitable locations for such care 
would include community pharmacies and outpatient 
clinics due to their compact size, efficient production 
and inexpensive nature. Further developments in FDM 
technology will allow for a more customized approach 
to modern day healthcare.
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Executive summary
•	 Alcohol misuse is a concern in the developed world and as such a range of treatment options are available.
•	 Oral regimens rely upon the patient strictly adhering to the prescriber’s directions with scope to miss doses if 
desired, implantable devices circumvent this issue as the drug is constantly delivered under the skin with time.
•	 Here, we considered the feasibility of loading a base material with disulfiram (which is frequently used in 
the management of alcohol misuse) and manufacturing 3D implantable devices to satisfy the personalized 
medicine paradigm.
•	 During production drug–base incompatibilities were apparent, which precluded effective implant 
manufacture.
•	 Thermal analysis confirmed drug–base incompatibilities with the thermal history of the resultant material 
influencing interfacial acid/base properties.
•	 A key issue during the manufacturing process was the high temperatures required to melt the base material; 
the elevated temperatures were not suitable for the material combination in this instance.
•	 We recommend that base materials of lower melting point are used in the 3D printing process, examples of 
which include PEG and oleic acid.
•	 3D printing holds great promise in the field of personalized, point-of-care disease management. However, 
careful consideration of drug-base incompatibilities is a must prior to the fabrication of pharmaceutically 
relevant dosage forms.
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